Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma | MicrobiomeTrials← Back to trialsNCT07349693
Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2027-04-01Est. Completion: 2029-03-30
Enrollment target: 175 participants Locations- Legorreta Cancer Center Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States
Other microbiome trials you might be interested in
Recurrent Glioblastoma, IDH-WildtypeRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 GliomaRecurrent WHO Grade 4 Glioma
This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treatin…
Chicago, United StatesEst. completion Jul 22, 2026
Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chem…
Phoenix, United StatesEst. completion Jun 30, 2027